Dana-Farber Cancer Institute is committed to providing expert, compassionate care to children and adults with cancer, while advancing the understanding, treatment, cure, and prevention of cancer and related diseases. The Institute is internationally renowned for its innovative research and clinical excellence. Our expertise in these two aspects of the fight against cancer uniquely position us to develop and … Read more
Over the last decade, significant strides have been made in understanding the molecular underpinnings of acute myelogenous leukemia (AML) in adults, which has led to better drugs and better treatment outcomes for patients. This shifting landscape now makes it possible for cancer researchers and providers to ask, “How can we do better?” Dana-Farber medical oncologist … Read more
Waldenström’s macroglobulinemia (WM) is a blood cancer that is extremely rare, affecting around 1500 people in the US each year. About 20 percent of those cases are considered familial, meaning that many members of the same family also have some form of blood cancer, such as myeloma or lymphoma. An even smaller group — five … Read more
Carcinoma of the prostate is a type of prostate cancer that occurs when normal prostate cells begin to grow uncontrollably. Carcinomas begin in the epithelial tissue—the thin tissue, like skin, that covers the linings of internal organs. Other cancers typically form in the body’s connective or supportive tissues (sarcomas), blood-forming tissue like bone marrow (leukemia), … Read more
It might sound counterintuitive, but not every patient comes to Dana-Farber for cancer treatment. For example, the Institute’s experts regularly see patients seeking help with benign (non-cancerous) blood disorders. Benign blood disorders such as anemia and sickle cell disease are often treated at cancer centers because such institutions are home to experts in hematology, which … Read more